Additionally, as early as 2014, the same group validated that elevated PTX3 expression could serve as a biomarker for predicting the progression from prostatic inflammation or BPH to prostate cancer (76), consistent with the findings of Ravenna L et al. Here, PTX3 is linked to prostate carcinoma.